Janssen: New pan-European survey reveals that only 14% of healthcare professionals feel sufficiently equipped to address prostate cancer patients’ quality of life issues
A new report released today entitled Prostate Cancer: Living, not Just Surviving , which details the findings from a large pan-European survey of 765 prostate cancer patients, 335 caregivers and 400 healthcare professionals, reveals that only 14 per cent of healthcare professionals feel that they have sufficient resources to address quality of life issues, such as fatigue, pain and intimacy problems. 1
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150915006448/en/
Developed by Janssen in collaboration with pan-European and national patient associations, the survey reveals that for the patients who experience chronic physical effects from the disease, fatigue (66%) has the biggest negative impact compared to disability and pain (41% and 22% respectively), particularly in metastatic patients (93%) and patients on medication (83%). Almost half of all men with prostate cancer surveyed (n=765) state that they are so tired, they no longer feel able to exercise and 74 per cent of this group say that this has had a negative effect on them emotionally.
It also suggests that men with prostate cancer worry more about quality of life issues associated with their disease, such as intimacy problems (54%) and feeling ill (41%), than dying (36%).
Professor Louis Denis, Onco-Urologist and Strategic Consultant, Europa Uomo said: “Prostate cancer is increasingly considered to be a chronic illness, as many men with the disease are now living longer. This opens up a new challenge for healthcare professionals, and the patients themselves, to place just as much focus on managing quality of life issues as they do on addressing survival.”
“Patient advocacy groups, such as Europa Uomo, can play an important role in supporting prostate cancer patients who are struggling emotionally and physically with their disease by providing the right up-to-date information on managing quality of life issues. They can also act as an avenue for patients and caregivers to connect and share their experiences with others who are living with the disease.”
The report reveals that almost all healthcare professionals (92%) surveyed believe that they proactively provide advice to patients on ways to improve their physical and emotional wellbeing. Conversely, only 14% of patients can recall their doctor advising them on ways to improve their physical and emotional well-being, aside from using medication.1
Dr Maria De Santis, Cancer Research Unit, University of Warwick, UK, said: “Communication is key. We hope that by having a greater understanding of the everyday individual experiences of patients and their caregivers, we as healthcare professionals, may be able to tailor the way we manage the disease to provide a more personalised and holistic approach to care.”
She continued: “Managing quality of life is extremely important in the overall process of caring for a patient with prostate cancer. However, many different methods of measuring quality of life exist, and healthcare professionals may not always be trained in or even aware of these methods. Healthcare professionals may therefore benefit from a single, simple, internationally-recognised quality of life measure to provide a consistent way to identify each patient’s needs.”
Jane Griffiths, Company Group Chairman, Janssen Europe, the Middle East and Africa (EMEA), said: “At Janssen we know that effective prostate cancer management goes beyond the provision of life-prolonging medicines. As prostate cancer is increasingly becoming a long-term and chronic disease, it is important that we work together to support men and their families to manage the quality of life issues related to the disease.”
“We hope that by shedding light on the experiences of patients, caregivers and healthcare professionals in Europe, this report will improve our understanding of how emotional, social issues and physical problems related to prostate cancer can be more effectively addressed through tailored personalised care.”
Latest prostate cancer figures show that there are currently three million men living with the disease in Europe2 and that the number is continuing to rise, with an increase of over 150% across more than a decade (1999 – 2012).3,4 Prostate cancer is the most commonly diagnosed cancer in men, with over 400,000 new cases diagnosed in Europe per year.3
The pan-European survey was carried out in ten countries across Europe by the independent research company, InSites Consulting. The Prostate Cancer: Living, not Just Surviving report can be viewed online at: http://www.janssen-emea.com/hpc/reports/Living-prostate-cancer
NOTES TO EDITORS
About the Prostate Cancer: Living not Surviving survey
The Prostate Cancer: Living, not Just Surviving survey was initiated on the recommendation of an independent European patient advocacy group panel, which identified a need to improve support for men with prostate cancer by focusing on the longer-term, holistic (quality of life) needs of them and their caregivers.
A pan-European survey was then carried out amongst 765 patients, 335 caregivers and 400 healthcare professionals to ascertain their views on the physical and emotional impact of prostate cancer. The survey was undertaken by the independent research company, InSites Consulting.
Participants were recruited from online research panels and through patient association group partners. Patients and caregivers were sourced from ten countries across Europe, including: the UK, Finland, France, Germany, Italy, Norway, Spain, Sweden, The Netherlands and Belgium. Healthcare professionals were surveyed in the UK, France, Germany, Spain and Italy.
The survey was developed and implemented in partnership with the following expert patient advocacy group panel members:
- Professor Louis Denis – Europa Uomo (EU)
- Christian Arnold – Association Nationale des Malades du Cancer de la Prostate (ANAMACAP) (FR)
- David Smith and Hugh Gunn – Prostate Cancer Support Federation (Tackle Prostate Cancer) (UK)
- Ian Banks – European Men’s Health Forum (EMHF) (EU)
- Calle Waller – Prostatacancerförbundet (SWE)
About European Prostate Cancer Awareness Day (EPAD)
EPAD 2015 is taking place in the European Parliament in Brussels on 16th September 2015, hosted and chaired by Mr P. De Backer MEP and co-chaired by Prof. C. Chapple, Secretary General of the European Association of Urology and Mr K. Mastris, Chairman of Europa Uomo.
EPAD 2015 aims to raise awareness, understanding and knowledge of the management of prostate diseases in general and prostate cancer in particular, and to highlight their significant impact on men across Europe and the burden on European social health care.
The event brings together key policy makers, scientific experts and European associations working in the urological field and representatives of European patient groups with an interest in prostate disease. During this event several experts will discuss the impact of living with benign prostatic enlargement and prostate cancer and how we can improve care and empower patients in the future.
About Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic castration-resistant prostate cancer occurs when cancer has metastasised (spread) beyond the prostate to other parts of the body and the disease progresses despite serum testosterone below castrate levels.5
The prostate is a gland in men that produces part of the seminal fluid and is located around the urethra (under the bladder). In some cases, cancer of the prostate can grow slowly. However, depending on factors including characteristics specific to the patient and the tumour, prostate cancer also can grow very quickly and spread widely.6
In 2012, over 400,000 new cases of prostate cancer were diagnosed in Europe, and nearly 92,000 men died from the disease.3
Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including in oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, hepatitis C and tuberculosis) and cardiovascular and metabolic diseases (e.g. diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare professionals, based on partnerships of trust and transparency. More information can be found on www.janssen-emea.com. Follow us on www.twitter.com/janssenEMEA for our latest news.
About Janssen in Oncology
In oncology, our goal is to fundamentally alter the way cancer is understood, diagnosed, and managed, reinforcing our commitment to the patients who inspire us. In looking to find innovative ways to address the cancer challenge, our primary efforts focus on several treatment and prevention solutions. These include disease area strongholds that focus on haematologic malignancies and prostate cancer; cancer interception with the goal of developing products that interrupt the carcinogenic process; biomarkers that may help guide targeted, individualised use of our therapies; as well as safe and effective identification and treatment of early changes in the tumour microenvironment.
# # #
1 ‘Prostate Cancer: Living not just surviving’ report. Available at: http://www.janssen-emea.com/hpc/reports/Living-prostate-cancer
2 European Commission. CORDIS Express: Prevention, diagnosis and treatment of prostate cancer. Available at: http://cordis.europa.eu/news/rcn/122705_en.html. Last accessed August 2015.
3 Ferlay J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Can. 2013;49:1374– 1403.
4 Sant M et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J of Can. 2009;45:931991.
5 Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010 September; 17 (Supplement 2): S72–S79.
6 Mayo Clinic. Prostate Cancer. Available at: http://www.mayoclinic.com/health/prostate-cancer/DS00043. Last accessed August 2015.
+44 (0)1494 567602
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
H.I.G. Capital Announces the Sale of KidsFoundation19.7.2018 19:50 | Pressemelding
H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €21 billion of equity capital under management, announced today that one of its affiliates has entered a definitive agreement to sell the KidsFoundation Group (“KidsFoundation”), the Dutch market leader in childcare services, to Onex Corporation (“Onex”)(TSX:ONEX). Terms were not disclosed. Headquartered in Almere, the Netherlands, KidsFoundation provides high-quality childcare to nearly 30,000 children between the ages of six weeks and 12 years. H.I.G. created KidsFoundation in 2014 through the acquisition of assets from the estate of Estro Group. During H.I.G.’s ownership, the company has developed strongly with significant capital invested by H.I.G. to create a high-quality childcare offering. H.I.G. worked with KidsFoundation management to optimise the footprint of the company by exiting loss-making locations, introduce new IT systems to drive operational improvement and develop an internal M&
SIG Combibloc Group Holdings S.à r.l.: 2018 Second Quarter Results19.7.2018 16:01 | Pressemelding
We are pleased to announce our quarterly conference call to discuss the results of SIG Combibloc Group Holdings S.à r.l. for the second quarter ended June 30, 2018. Date: Monday, July 23, 2018 Time: 15.00 CEST / 14.00 BST / 9.00 EDT The call information will be distributed on our secure site. If you would like access to our call, please contact email@example.com . Regards, SIG Combibloc Group Holdings S.à r.l. View source version on businesswire.com: https://www.businesswire.com/news/home/20180719005634/en/ Contact information SIG Combibloc Group Holdings S.à r.l. Jennifer Gough firstname.lastname@example.org
NEORIS Announces Creation of Innovation Labs Worldwide to Create a Smarter Future19.7.2018 15:32 | Pressemelding
NEORIS, a global digital consulting services company, announced today it is consolidating the most innovative solutions it has developed in different geographies and allocating unprecedented resources to deploy a network of Innovation Labs worldwide. The main objective is to lay the foundation for the continuous development of disruptive solutions for its four core industries: Manufacturing, Financial Services, Healthcare and Telecommunications. Due to its disruptive nature, NEORIS decided that its first Innovation Lab should be housed in the Monterrey Digital Hub, which today is the first-of-its-kind as it is a space where entrepreneurs, companies, universities and investors converge to foster an ecosystem for Digital Transformation. The lab inaugurated in Monterrey, Mexico is the first of a series of Innovation Labs that will open in the different countries that NEORIS operates, and is a space where customers can experience emerging technologies through real-life scenarios. One such
CORRECTING and REPLACING Albar Capital Deploys FlexNOW19.7.2018 15:29 | Pressemelding
Subhead of release should read: Out-of-the-Box Multi-Asset Execution Management System (instead of Easy-to-Install Multi-Asset Execution Management System). The corrected release reads: ALBAR CAPITAL DEPLOYS FLEXNOW Out-of-the-Box Multi-Asset Execution Management System FlexTrade (@FlexTrade) today announced that Albar Capital Ltd., a new hedge fund led by Javier Velazquez (formerly of Millennium Capital Partners LLP), is now trading equities and futures using FlexNOW, FlexTrade’s new execution management system. “The FlexNOW team was instrumental in solving several of our problems,” said Jason Ruder, Trader at Albar Capital. “Not only are they helping us with our compliance requirements, they are also responsive to requests that improve my workflow.” According to Rhyd Lewis, FlexNOW Product Manager, FlexNOW’s quick onboarding and easy installation process was critical for Albar Capital’s launch on 2 July. “We had no problem integrating FlexNOW with Albar’s portfolio and risk managemen
Full Core of Westinghouse Fuel Achieved at South-Ukraine Nuclear Power Plant Unit 319.7.2018 13:25 | Pressemelding
Westinghouse Electric Company announced today that Ukraine’s State Enterprise National Nuclear Energy Generation Company (SE NNEGC) Energoatom’s South-Ukraine NPP Unit 3 near Yuzhnoukrainsk in Mykolaiv province was loaded with a full core of Westinghouse VVER-1000 fuel. This is the first unit in Ukraine to operate with Westinghouse VVER-1000 fuel assemblies as the sole fuel source. “Westinghouse began supplying fuel to Ukraine in 2005, when the first lead test assemblies were delivered to South-Ukraine Unit 3,” said Aziz Dag, vice president and managing director, Northern Europe. “We are proud to continue supporting Ukraine with their energy diversification by supplying a full core of Westinghouse VVER-1000 fuel to our customer, Energoatom.” Westinghouse currently supplies fuel to six of Ukraine’s 15 nuclear power reactors. Beginning in 2021, the number of reactors with Westinghouse fuel will increase to seven. “Westinghouse has made significant investments over the last several years
Seoul Semiconductor Delivers Its Innovative LED "SunLike" to U.S. Lighting Market19.7.2018 13:00 | Pressemelding
Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a market leader in LED (light emitting diode) design and manufacturing, announced that its innovative LED “SunLike” is applied to brand new lightings to be launched by three lighting premium brands in U.S., Pure Edge Lighting, LEDRAbrands, Inc. and Elite Lighting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180719005377/en/ The product of LEDRAbrands, Inc., NU4RA-SUN, which applied SunLike of Seoul Semiconductor (Photo: Business Wire) Seoul Semiconductor supplies SunLike to pendant lighting for Pure Edge, a U.S. lighting solution company. It is applied to high-end lighting for museums and art galleries that require the highest color quality. The leading lighting design companies, LEDRAbrands, Inc. and Elite Lighting, apply SunLike to downlights and spotlights respectively. “We have selected Seoul Semiconductor’s innovative LED SunLike for our human centric lighting and believ